How Rheumatoid Arthritis Causes Anemia
Rheumatoid arthritis causes anemia primarily through IL-6-mediated hepcidin overproduction, which blocks iron release from storage sites and suppresses bone marrow erythropoiesis, while TNF-α directly induces apoptosis of erythroid precursor cells.
Primary Mechanisms
Hepcidin-Mediated Iron Sequestration
The dominant pathway involves inflammatory cytokines, particularly IL-6, driving excessive hepcidin production 1, 2, 3. Hepcidin binds to ferroportin on iron-secreting cells (macrophages, enterocytes, hepatocytes), causing its degradation and preventing iron release into circulation 3. This creates functional iron deficiency—iron is trapped in storage sites despite adequate total body stores, starving the bone marrow of iron needed for hemoglobin synthesis 2.
- Serum hepcidin levels are significantly elevated in RA patients with anemia of chronic disease (ACD) compared to controls 2
- Hepcidin correlates positively with ferritin but negatively with hemoglobin, serum iron, and transferrin saturation 2
- This explains the characteristic laboratory pattern: low serum iron, low transferrin saturation, but normal or elevated ferritin
Direct Bone Marrow Suppression
TNF-α causes direct apoptotic death of erythroid precursor cells in the bone marrow 4. Patients with active RA demonstrate:
- Reduced numbers of CD34+/CD71+ and CD36-/glycophorin A+ erythroid cells
- Increased apoptosis within these erythroid compartments (up to 3-fold higher than controls)
- Decreased erythroid burst-forming units (BFU-Es) 4
TNF-α levels in bone marrow culture supernatants inversely correlate with hemoglobin levels and BFU-E numbers 4. Anti-TNF-α therapy normalizes these abnormalities and improves hemoglobin levels, confirming TNF-α's causative role 4, 5.
IL-6 as the Central Mediator
IL-6 emerges as the most important cytokine in multivariate analysis, remaining an independent predictor of hemoglobin levels even after controlling for other inflammatory markers 1. This dual action—stimulating hepcidin production AND directly suppressing erythropoiesis—makes IL-6 the linchpin of RA-associated anemia 1, 3.
Clinical Prevalence and Patterns
Anemia affects 25-54% of RA patients depending on disease activity 1, 6:
- Anemia of chronic disease (ACD): 37% of patients 2
- True iron deficiency anemia (IDA): 12-15% 7, 2
- Combined ACD/IDA: 18% 2
- Total iron deficiency (functional + absolute): 60-64% in active disease 7
Key associations:
- Higher disease activity (DAS28) correlates with lower hemoglobin 6
- Elevated CRP and ESR strongly associate with anemia presence 1, 6
- Longer disease duration increases anemia risk 6
Distinguishing Features
The anemia is typically normocytic or microcytic, with:
- Low serum iron and transferrin saturation (<20% in 43% of patients) 7
- Normal or elevated ferritin (though ferritin <100 μg/L may still indicate iron deficiency in inflammatory states) 8
- Elevated soluble transferrin receptor (sTfR) in 26% 7
- Inappropriately low erythropoietin response for the degree of anemia 1
Critical Pitfall
Do not assume all anemia in RA is inflammatory—approximately one-third of patients have true iron deficiency (alone or combined with ACD) requiring different management 2. Ferritin can be falsely elevated as an acute phase reactant, masking concurrent iron deficiency. Consider transferrin saturation <20% and elevated sTfR as better indicators of true iron deficiency in the inflammatory context 7, 2.